This study identifies CREBBP mutations as a targetable vulnerability in B-ALL, showing that CREBBP inhibition sensitizes these cells to Venetoclax-induced ferroptosis.

bioRxiv · Oct 2, 2023 · PreprintCancer Biology

HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia

S. Agrawal Singh, J. Bagri, G. Giotopoulos, D. Azazi, S. J. Horton, J. W. Houghton, S. Anand, A. S. Bach, F. Stedham, R. Antrobus, G. Vassiliou, D. Sasca, H. Yun, A. Whetton, B. J. P. Huntly

This study identifies a repressive HOXA9-SAFB complex in AML that maintains disease by inhibiting differentiation and apoptosis, suggesting therapeutic targets.

bioRxiv · Oct 12, 2022 · PreprintCancer Biology

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation

V. Shah, G. Giotopoulos, H. Osaki, M. Meyerhoefer, E. Meduri, B. Schubert, H. Yun, S. J. Horton, S. Agrawal-Singh, P. S. Haehnel, F. Basheer, D. Lugo, M. W. Kuehn, B. Guezguez, M. Theobald, , D. Sasca

This study identifies p300-mediated compensatory transcriptional programs that drive acute resistance to BET inhibitors in AML and suggests sequential BET- and p300-inhibition as a therapeutic strategy.

bioRxiv · Sep 14, 2022 · PreprintCancer Biology

Mutational synergy coordinately remodels chromatin accessibility, enhancer landscape and 3-Dimensional DNA topology to alter gene expression during leukemia induction

H. Yun, S. Vohra, A. Mupo, G. Giotopoulos, D. Sasca, S. J. Horton, S. Agrawal-Singh, E. Meduri, F. Basheer, L. Marando, M. Gozdecka, O. M. Dovey, A. Castillo-Venzor, X. Wang, P. Gallipoli, , B. J. P. Huntly

The paper investigates how mutations synergize to alter chromatin accessibility, enhancer landscapes, and 3D DNA topology in leukemia induction using a murine model.

bioRxiv · Mar 20, 2020Cancer Biology